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SREBP1c-CRY1 signalling represses hepatic glucose
production by promoting FOXO1 degradation
during refeeding
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SREBP1c is a key lipogenic transcription factor activated by insulin in the postprandial state.
Although SREBP1c appears to be involved in suppression of hepatic gluconeogenesis, the
molecular mechanism is not thoroughly understood. Here we show that CRY1 is activated by
insulin-induced SREBP1c and decreases hepatic gluconeogenesis through FOXO1 degradation,
at least, at speciﬁc circadian time points. SREBP1c / and CRY1 / mice show higher blood
glucose than wild-type (WT) mice in pyruvate tolerance tests, accompanied with enhanced
expression of PEPCK and G6Pase genes. CRY1 promotes degradation of nuclear FOXO1 by
promoting its binding to the ubiquitin E3 ligase MDM2. Although SREBP1c fails to upregulate
CRY1 expression in db/db mice, overexpression of CRY1 attenuates hyperglycaemia through
reduction of hepatic FOXO1 protein and gluconeogenic gene expression. These data suggest
that insulin-activated SREBP1c downregulates gluconeogenesis through CRY1-mediated
FOXO1 degradation and that dysregulation of hepatic SREBP1c-CRY1 signalling may contribute
to hyperglycaemia in diabetic animals.
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I
nsulin, which is released from pancreatic b-cells, plays a
key role in the maintenance of the whole body energy
homoeostasis by actively regulating glucose and lipid meta-
bolism. In the postprandial state, insulin lowers blood glucose by
stimulating glucose uptake in adipose tissues and muscles as well
as by inhibiting hepatic glucose production1,2. Moreover, in the
liver, insulin stimulates the conversion of excess glucose into
glycogen (glycogenesis) and triacylglyceride (lipogenesis) for the
long-term energy storage3–5.
Suppression of hepatic gluconeogenesis by insulin is an
important process to inhibit hyperglycaemia. PEPCK and G6Pase
are crucial enzymes that convert pyruvate to glucose, and their
gene expression is regulated by several transcription factors
such as Forkhead box O1 (FOXO1), cAMP response element-
binding protein (CREB), hepatocyte nuclear factor 4 (HNF4),
glucocorticoid receptor and peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (PGC1a)6–8. In the liver,
FOXO1 is activated on fasting and gets inactivated by feeding,
which is one of the essential mechanisms by which insulin
rapidly and efﬁciently represses hepatic glucose production
during postprandial periods9–11. After insulin treatment,
FOXO1 protein is phosphorylated by AKT and then moves to
the cytoplasm, resulting in the decrease of gluconeogenic gene
expression12. Although the translocation of hepatic FOXO1 from
the nucleus to the cytoplasm is a well-deﬁned mechanism
mediating a quick decrease in glucose production by insulin, it is
largely unknown how insulin endows a sustainable inhibition of
hepatic gluconeogenesis throughout the postprandial state.
On the other hand, SREBP1c has been proposed to be involved
in the regulation of hepatic glucose metabolism. SREBP1c is a
basic-helix-loop-helix-leucine zipper (bHLH-LZ) transcription
factor that regulates de novo lipogenesis13–17. Activation of
SREBP1c is mediated by AKT and mTORC1 on insulin
signalling18,19. SREBP1c regulates lipogenic pathways by
stimulating the expression of target genes such as those
encoding fatty acid synthase (FASN), stearoyl-CoA desaturase 1
(SCD1), and acetyl-coenzyme A carboxylase (ACC)20–22. In
addition, SREBP1c appears to regulate hepatic carbohydrate
metabolism. For example, SREBP1c affects the mRNA levels of
PEPCK, G6Pase and IRS-2 genes and inhibits the interaction
between HNF4 and PGC1a to suppress gluconeogenic genes23–27.
Although hepatic SREBP1c has been reported to be upregulated
in obese animals, the reason why increased SREBP1c fails to
repress hepatic gluconeogenesis is unknown. Thus, understanding
the molecular mechanisms by which SREBP1c could modulate
gluconeogenesis under physiological and pathological conditions
is important.
CRY1 is a member of the mammalian clock genes regulated by
transcription–translation feedback loop that also includes
CLOCK, BMAL1, PER1, PER2 and CRY2, to modulate rhythmic
oscillations. CLOCK and BMAL1 form a heterodimer to activate
PER and CRY genes and then elevated PER and CRY proteins act
as transcriptional repressors that decrease the transcriptional
activity of CLOCK and BMAL1 (refs 28–31). The hepatic
circadian clock is regulated by food intake and by the
expression of hormones such as insulin and glucagon, whereas
the suprachiasmatic nucleus circadian clock is controlled by the
light–dark cycle32. Recently, it has been shown that hepatic
circadian clock genes also contribute to glucose homoeostasis. For
example, hepatic CRY proteins modulate glucose production by
inhibiting the glucagon receptor signalling pathway and binding
to glucocorticoid receptor33,34. In addition, an agonist of CRY
proteins has been reported to repress the expression of hepatic
gluconeogenic genes, such as PEPCK and G6Pase35. Furthermore,
BMAL1 / mice exhibited disrupted hepatic glucose
homoeostasis36. However, the molecular mechanisms by which
CRY1 could repress hepatic glucose production during the
postprandial state remain to be elucidated.
The fact that SREBP1c downregulates hepatic gluconeogenesis
prompted us to investigate novel target genes of SREBP1c
by comparing SREBP1cþ /þ and SREBP1c / mice. Here we
demonstrate that SREBP1c attenuates hepatic glucose production
via the activation of CRY1 at certain circadian time points
(particularly at ZT 3), eventually leading to degradation of the
FOXO1 protein on insulin signalling. While hepatic FOXO1 is
rapidly translocated from the nucleus into the cytoplasm by AKT-
mediated phosphorylation triggered by insulin, the SREBP1c-
CRY1 signalling pathway durably represses the execution of
gluconeogenic genes by decreasing nuclear FOXO1 protein for
long-term insulin action. In addition, in the liver of diabetic db/db
mice, overexpression of CRY1 lowers blood glucose, accompanied
with attenuated gluconeogenic gene expression and FOXO1
protein. Altogether, our data suggest that insulin activates
the SREBP1c-CRY1 signalling pathway, resulting in FOXO1
degradation mediated by MDM2, which is one of the crucial
mechanisms to maintain hepatic glucose homoeostasis.
Results
CRY1 is upregulated by feeding and insulin. In the liver,
peripheral circadian clock genes are regulated by various
nutritional and hormonal changes37. Given that circadian clock
genes are closely associated with energy homoeostasis, we sought
to investigate which circadian clock genes could affect feeding-
dependent hepatic lipid and glucose metabolism. Since the
expression of most circadian clock genes oscillates in a time
dependent manner, the end points of the fasting and/or refeeding
experiment were ﬁxed at ZT 3. On refeeding, the expression
of lipogenic genes including SREBP1c, FASN and ACC was up-
regulated in the liver. In accordance with previous reports38–40,
the expression of gluconeogenic genes such as PEPCK and
G6Pase was downregulated in the postprandial state (Fig. 1a,
Supplementary Fig. 1A). Interestingly, the level of hepatic CRY1
mRNA was elevated in refed mice (Fig. 1a). Moreover, the
expression of the CRY1 protein was markedly increased in the
liver of refed mice at ZT 3 (Fig. 1b, Supplementary Fig. 1B).
Because CRY1 is one of core circadian clock genes, we
investigated the expression of CRY1 gene at ZT 22 and ZT 10,
which are the peak and trough time point of CRY1 expression,
respectively31. On refeeding, the expression of many circadian
clock genes including CRY1, BMAL1, CLOCK, PER1, PER2 and
Reverbs was signiﬁcantly changed at ZT 22, but mostly not at ZT
10 (Supplementary Fig. 2). While basal levels of CRY1 expression
were differently regulated at ZT 22 and ZT 10, refeeding
increased CRY1 mRNA and protein levels at ZT 22, compared
with ZT 10. These results imply that CRY1 expression would be
modulated by nutritional stimuli at certain ZT time points
(Supplementary Fig. 2). These ﬁndings prompted us to test
whether insulin might elevate hepatic CRY1 gene expression. In
primary hepatocytes, the level of CRY1 mRNA was increased by
insulin, similar to SREBP1c mRNA (Fig. 1c). Altogether, these
data propose that hepatic CRY1 expression would be upregulated
by feeding and insulin.
SREBP1c regulates CRY1 gene expression. To investigate which
transcription factors regulate insulin-dependent CRY1 gene
expression, we analysed CRY1 promoters in several species
including monkey, cow, sheep, human, rat and mouse
(Supplementary Fig. 3A). In the proximal CRY1 promoter, there
are several sterol regulatory element (SRE) motifs as well as an
E-BOX (CANNTG) motif, which is also a target motif for
BMAL1 and CLOCK, the core circadian clock proteins
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(Supplementary Fig. 3A). Both SRE and E-BOX motifs are
well-known binding targets of SREBP1c with its dual DNA
binding speciﬁcity41,42. To examine whether SREBP1c could
regulate CRY1 gene expression, SREBP1c was overexpressed in
mouse primary hepatocytes. As shown in Fig. 2a,b, the levels of
hepatic CRY1 mRNA and CRY1 protein were increased by
SREBP1c overexpression (Fig. 2a,b, Supplementary Fig. 4A),
implying that SREBP1c may be a key transcription factor that
upregulates hepatic CRY1 gene expression in the postprandial
state. Next, the effect of ectopic expression of SREBP1c on the
CRY1 promoter activity was examined. Expression of luciferase
from a wild-type CRY1 promoter was compared with the
expression from a promoter with mutated SRE motifs (3XSRE)
in HEK293T cells (Fig. 2c). We observed substantial loss of
promoter activity with loss of the 3XSRE sequences but not
E-BOX motif sequences (Fig. 2c, Supplementary Fig. 3B). In
addition, SREBP1c binding to the CRY1 promoter was conﬁrmed
by a ChIP assay (Fig. 2d). Meanwhile, consistent with previous
reports23–25, hepatic SREBP1c reduced G6Pase and PEPCK
expression (Fig. 2a).
To investigate whether SREBP1c might promote CRY1
gene expression on insulin, primary hepatocytes isolated from
SREBP1cþ /þ and SREBP1c / mice were challenged with
insulin. The level of CRY1 protein in SREBP1cþ /þ primary
hepatocytes was prominently elevated by insulin whereas that
of CRY1 protein in SREBP1c / primary hepatocytes was
increased to a lesser extent by insulin (Fig. 2e). Moreover, in
contrast to SREBP1cþ /þ mice, refeeding failed to increase
hepatic CRY1 gene expression in SREBP1c / mice (Fig. 2f).
These data indicate that SREBP1c is a key factor for the
upregulation of hepatic CRY1 gene expression in the postprandial
state.
SREBP1c-CRY1 pathway inhibits hepatic gluconeogenesis.
Consistent with previous reports25,33,34, SREBP1c overexpression
decreased glucose production in mouse primary hepatocytes
(Fig. 3a). In addition, the optical in vivo imaging analysis revealed
that hepatic SREBP1c overexpression remarkably repressed the
promoter activity of the G6Pase gene in vivo (Fig. 3b).
Accordingly, the expression of G6Pase and PEPCK genes was
suppressed in the liver of SREBP1c overexpressing mice
(Supplementary Fig. 4B). These ﬁndings led us to investigate
the effect of SREBP1c on blood glucose level in vivo. Pyruvate
tolerance test revealed that the adenoviral overexpression of
SREBP1c signiﬁcantly decreased the level of blood glucose
following pyruvate injection (Fig. 3c,d). Also, SREBP1c /
mice showed higher blood glucose than SREBP1cþ /þ mice
(Fig. 3e,f). Thus, these results suggest that hepatic SREBP1c
would suppress gluconeogenesis, potentially by modulating
gluconeogenic gene expression.
To examine whether CRY1, a novel target gene of SREBP1c,
might modulate hepatic gluconeogenic gene expression, we
suppressed CRY1 expression via small interfering RNA (siRNA)
in rat hepatoma H4IIE cells. Downregulation of CRY1 increased
the expression of G6Pase and PEPCK genes (Fig. 3g,
Supplementary Fig. 5A), which are crucial for hepatic gluconeo-
genesis. On the contrary, hepatic CRY1 overexpression decreased
the expression of G6Pase and PEPCK genes in mouse primary
hepatocytes (Fig. 3h, Supplementary Fig. 5B). To conﬁrm these
observations, we measured pyruvate-induced blood glucose level
from CRY1þ /þ and CRY1 / mice. As shown in Fig. 3i,j,
CRY1 / mice exhibited higher blood glucose level than
CRY1þ /þ mice. To test whether CRY1 would be a key mediator
of the inhibition of hepatic gluconeogenesis by SREBP1c, glucose
production assays were performed in primary hepatocytes from
CRY1þ /þ and CRY1 / mice. As indicated in Fig. 3k and
Supplementary Fig. 5C, SREBP1c overexpression attenuated
glucose production in CRY1þ /þ primary hepatocytes while
SREBP1c failed to suppress glucose production in CRY1 /
primary hepatocytes. To establish whether the SREBP1c-CRY1
signalling pathway could indeed repress hepatic glucose produc-
tion in vivo, CRY1 was adenovirally overexpressed in the liver of
35
30
25
20
15
10
5
0R
el
at
iv
e 
m
R
N
A 
le
ve
ls **
Lipogenesis
**
* *
SR
EB
P1
c
SR
EB
P1
a
SR
EB
P2
FA
SN AC
C
6
5
4
3
2
1
0R
el
at
iv
e 
m
R
N
A 
le
ve
ls
Circadian clock
**
PE
R2
BM
AL
1
CL
OC
K
CR
Y1
CR
Y2
1.4
1.2
1
0.8
0.6
0.4
0.2
0R
el
at
iv
e 
m
R
N
A 
le
ve
ls
Gluconeogenesis
Fasted
Refed
**
**
PE
PC
K
G6
Pa
se
Mouse liver
Fasted Refed
pSREBP1
nSREBP1
CRY1
ACTIN
130
70
70
40
5.0
4.0
3.0
2.0
1.0
0R
el
at
iv
e 
m
R
N
A 
le
ve
ls
***
*
SR
EB
P1
c
FA
SN
CR
Y1
BM
AL
1
CR
Y2
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0
***
***
R
el
at
iv
e 
m
R
N
A 
le
ve
ls PBS
Insulin
G6
Pa
se
PE
PC
K
a
b c
Figure 1 | CRY1 is stimulated by feeding and exposure to insulin. (a,b) C57BL/6 mice were fasted for 24 h and then refed for 12 h. Both fasted and
refed mice were sacriﬁced at ZT 3. In the liver, levels of the CRY1 mRNA (a) and CRY1 protein (b) were determined using qRT-PCR with normalization to
TBP mRNA levels and western blotting, respectively. pSREBP1, precursor SREBP1; nSREBP1, nuclear SREBP1. Data are represented as mean±s.d., N¼ 3 for
each group. *Po0.05, **Po0.01 (Student’s t-test). (c) CRY1 gene expression was measured in mouse primary hepatocytes following 12 h of insulin
exposure using qRT-PCR. The level of the TBP mRNA was used for the qRT-PCR normalization. Data are represented as mean±s.d., N¼ 3 for each group.
*Po0.05, ***Po0.001 (Student’s t-test). See Supplementary Fig. 13 for original full immunoblot.
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SREBP1c / mice. While SREBP1c / mice showed higher
blood glucose level than SREBP1cþ /þ mice during the pyruvate
tolerance test, SREBP1c / mice with CRY1 overexpression
decreased blood glucose level (Fig. 3l,m, Supplementary Fig. 6A,B).
These data strongly indicate that the SREBP1c-CRY1 signalling
pathway could inhibit hepatic gluconeogenesis in vivo.
CRY1 regulates FOXO1 protein levels. To decipher the
underlying mechanism(s) by which insulin-induced CRY1 could
repress hepatic gluconeogenesis, we focused on FOXO1, as its
regulatory effects on insulin signalling and gluconeogenesis are
well established. In mouse primary hepatocytes, the level of
FOXO1 protein was decreased by CRY1 overexpression (Fig. 4a)
while FOXO1 mRNA levels were not altered (Fig. 4b). These data
indicated that CRY1 might modulate the level of FOXO1 protein,
probably, independent of FOXO1 mRNA. Furthermore, the level
of FOXO1 protein was enhanced in CRY1 suppressed hepatocytes
(Fig. 4c,d). In accordance with these in vitro data, the level of
FOXO1 protein was higher in the liver of CRY1 / mice than in
the liver of CRY1þ /þ mice, whereas the levels of FOXO1 mRNA
were not different between CRY1þ /þ and CRY1 / mice
(Fig. 4e,f). Compared with SREBP1cþ /þ mice, the levels of
FOXO1 protein and G6Pase and PEPCK mRNAs were
augmented in the liver of SREBP1c / mice whereas that of
CRY1 protein was reduced (Fig. 4g, Supplementary Fig. 7).
To verify that CRY1 could inhibit hepatic gluconeogenesis via
FOXO1, the effects of CRY1 and/or FOXO1 suppression on
gluconeogenic gene expression were examined. Increased
expression of G6Pase and PEPCK genes by CRY1 suppression was
abolished when FOXO1 gene was downregulated by siRNA
(Fig. 4h), implying that FOXO1 might be a downstream factor of
CRY1 to regulate gluconeogenesis. These in vivo and in vitro data
imply that CRY1 would alleviate hepatic gluconeogenesis through
FOXO1.
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Ad-SREBP1c. Relative glucose production was measured using a glucose oxidase (GO) kit. Data represent mean±s.d., N¼ 8 for each group. ***Po0.001
versus Ad-MOCK, ###Po0.001 versus CRY1þ /þ (Student’s t-test). (l,m) Pyruvate tolerance test (l) in SREBP1cþ /þ mice injected with Ad-MOCK and in
SREBP1c / mice injected with either Ad-MOCK or Ad-CRY1. Results were converted to AUC (m). All mice were fasted at ZT 10 and performed PTT at
ZT 3. Data represent mean ±s.d., N¼ 7–10 for each group. **Po0.01, ***Po0.001 versus SREBP1cþ /þ , Ad-MOCK, #Po0.05, ###Po0.001 versus
SREBP1c / , Ad-MOCK (Student’s t-test).
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FOXO1 protein is decreased by insulin-activated CRY1.
FOXO1 translocation from the nucleus to the cytoplasm by AKT
is a well-known mechanism by which insulin acutely inhibits
hepatic glucose production43. As insulin upregulates CRY1 that,
in turn, downregulates the FOXO1 protein (Figs 1c and 4a),
we investigated the time course of these events by examining
the expression proﬁles of FOXO1 and CRY1 proteins in
insulin-treated primary hepatocytes. As shown in Fig. 5a,
phosphorylation of AKT and FOXO1 was clearly induced in
cells treated with insulin for a relatively short periods (0–4 h).
Consistent with previous report44, the level of FOXO1 protein
was decreased by short-term insulin treatment (0B4 h), which
would be mediated by FOXO1 ubiquitination and degradation in
cytosol. Furthermore, the phosphorylation levels of AKT and
FOXO1 were gradually and substantially decreased by a long-
term incubation (8–12 h) with insulin. It appears that FOXO1
translocation from the nucleus to the cytoplasm by AKT might
be more pronounced after a short exposure (0–4 h) to insulin
rather than following a long-term insulin treatment (8–12 h).
Intriguingly, in hepatocytes treated with insulin for long periods
(8–12 h), the level of the CRY1 protein was markedly increased,
while that of the total FOXO1 protein was continuously
decreased, implying that the amount of the CRY1 protein
appears to be inversely related to the total quantity of the FOXO1
protein. Accordingly, the expression of PEPCK and G6Pase genes
was downregulated after either a long-term (8–12 h) or a short-
term (0–4 h) insulin treatment (Fig. 5b). These data suggest that
sustainable reduction of the FOXO1 protein might be involved in
the suppression of hepatic gluconeogenesis for long-term insulin
action.
Next, we explored whether CRY1 could indeed modulate the
FOXO1 protein in insulin-treated hepatocytes. To address this,
we have tested CRY1þ /þ and CRY1 / primary hepatocytes.
As shown in Fig. 5c, the level of FOXO1 protein was decreased in
insulin-treated CRY1þ /þ primary hepatocytes while that of
FOXO1 protein was not continuously suppressed in insulin-
treated CRY1 / primary hepatocytes. In the late phase of insulin
action, decreased levels of PEPCK and G6PasemRNA were slightly
but substantially increased in CRY1 / primary hepatocytes
(Fig. 5d). Moreover, insulin failed to suppress glucose production
in long-term (8–12 h) insulin-treated CRY1 / primary
hepatocytes. (Fig. 5e). Altogether, these data indicate that CRY1
could repress the expression of hepatic gluconeogenic genes with
reduced FOXO1 protein for the long-term insulin action (8–12 h).
70
70
40
Ad-MOCK Ad-CRY1
CRY1
FOXO1
ACTIN
2.0
1.5
1.0
0.5
0.0
R
el
at
iv
e 
m
R
N
A
le
ve
ls
Ad-MOCK
Ad-CRY1
*
*
PE
PC
K
G6
Pa
se
FO
XO
1
D
AP
I
FO
XO
1
M
er
ge
siCON siCRY
Cell lysates
siCON siCRY1
CRY1
FOXO1
ACTIN
70
70
40
Liver lysates
70
70
40
CRY1+/+ CRY1–/–
CRY1
FOXO1
ACTIN
3.5
3
2.5
2
1.5
1
0.5R
el
at
iv
e 
m
R
N
A
le
ve
ls *
*
0
G6
Pa
se
PE
PC
K
FO
XO
1
Liver lysates
CRY1+/+
CRY1–/–
SREBP1c+/+
130
70
70
70
40
pSREBP1
nSREBP1
CRY1
FOXO1
ACTIN
1.4
1.2
1
0.8
0.6
0.4
0.2
0
PEPCK
*
*
##
R
el
at
iv
e 
m
R
N
A
le
ve
ls
siC
ON
siC
RY
1
siF
OX
O1
siC
RY
1 +
 
siF
OX
O1
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
siC
ON
siC
RY
1
siF
OX
O1
siC
RY
1 +
 
siF
OX
O1
#
*
*
G6Pase
1.2
1
0.8
0.6
0.4
0.2
0
siC
ON
siC
RY
1
siF
OX
O1
siC
RY
1 +
 
siF
OX
O1
siC
ON
siC
RY
1
siF
OX
O1
siC
RY
1 +
 
siF
OX
O1
** **
*** ***
CRY1 FOXO1
1.2
1
0.8
0.6
0.4
0.2
0
a b c
d
e
f g
h
SREBP1c–/–
Figure 4 | CRY1 regulates FOXO1 protein level. (a,b) Mouse primary hepatocytes were adenovirally infected with Ad-MOCK or Ad-CRY1. The
expression proﬁles of FOXO1 were analysed at the protein level (a) using western blotting and at the mRNA level (b) using qRT-PCR. Data are represented
as mean±s.d., N¼4 for each group. *Po0.05 (Student’s t-test). (c,d) H4IIE cells were transfected with siCON or siCRY1. Immunocytochemical analysis
(c) of endogenous FOXO1. DAPI, 4’, 6-diamidino-2-phenylindole. Scale bars, 10mm. Endogenous FOXO1 and CRY1 protein levels were analysed using
western blotting (d). (e,f) The expression patterns of FOXO1 protein in the liver of CRY1þ /þ and CRY1 / mice were analysed by western blotting
(e) and qRT-PCR (f). Relative mRNA levels were determined using qRT-PCR and normalized to the levels of the TBP mRNA. Data are represented as mean
±s.d., N¼ 3 for each group. *Po0.05, (Student’s t-test). (g) Expression of CRY1 and FOXO1 proteins in the liver of SREBP1cþ /þ and SREBP1c / mice
was analysed by western blotting. (h) H4IIE cells were co-transfected with siCRY1 and/or siFOXO1. Relative mRNA levels were determined using qRT-PCR
and normalized to the cyclophilin mRNA level. Data are represented as mean ±s.d., N¼ 3 for each group. #Po0.05, ##Po0.01 versus siCRY1, *Po0.05,
**Po0.01, ***Po0.001 versus siCON (Student’s t-test). See Supplementary Fig. 13 for original full immunoblot.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12180
6 NATURE COMMUNICATIONS | 7:12180 | DOI: 10.1038/ncomms12180 | www.nature.com/naturecommunications
To test whether enhanced CRY1 could suppress hepatic
gluconeogenesis even in the absence of a short-term insulin
action (0B4 h), we employed AKT inhibitors. In primary
hepatocytes, insulin increased phosphorylation levels of both
AKT and FOXO1, while a co-treatment with the AKT inhibitor
AKTVIII blocked phosphorylation of both proteins, as expected
(Fig. 5f). However, in CRY1-overexpressing hepatocytes, the total
FOXO1 level was decreased in insulin and/or the AKT inhibitor
Insulin: 0 h 0.5 h 2 h 4 h 8 h 12 h
CRY1
pAKT
AKT
pFOXO1
FOXO1
ACTIN
70 1.4
70
70
55
70
70
40
1.2
1
0.8
0.6
0.4
0.2
0
Insulin:
R
el
at
iv
e 
m
R
N
A 
le
ve
ls
PEPCK
*
***
0 h0.5
 h 2 h 4 h 8 h 12
 h
1.2
1
0.8
0.6
0.4
0.2
0
0 h0.5
 h 2 h 4 h 8 h12
 h
***
*
PBS Insulin
G6Pase
0 h 2 h 4 h 8 h 12 h 0 h 2 h 4 h 8 h 12 h
70
70
70
55
70
70
40
Insulin:
CRY1
pAKT
AKT
pFOXO1
FOXO1
ACTIN
CRY1+/+ CRY1–/–
1.4
1.2
1
0.8
0.6
0.4
0.2
0R
el
at
iv
e 
m
R
N
A 
le
ev
el
s PEPCK
Insulin:
0 h 2 h 4 h 8 h 12
 h 0 h 2 h 4 h 8 h 12
 h
1.2
1
0.8
0.6
0.4
0.2
0
*** **
G6Pase
CRY1+/+ CRY1–/–
*
*
*
Ad-MOCK Ad-CRY1
Insulin:
AKT VIII:
CRY1
pAKT
AKT
pFOXO1
FOXO1
ACTIN
–
– –
–
– –
+
+
++
+
+CRY1
+/+ CRY1–/–
**
*
1.2
1
0.8
0.6
0.4
0.2
0
Insulin:
R
el
at
iv
e 
gl
uc
os
e 
pr
od
uc
tio
n
0 h 2 h 4 h 8 h 12
 h
70
70
55
55
70
70
40
Ad-MOCK Ad-CRY1
Vehicle MK2206 MK2206
FOXO1
CRY1
short exposure
CRY1
Long exposure
ACTIN
70
70
70
40
*
###
2.5
2
1.5
1
0.5A
UC
 g
lu
co
se
 (P
TT
)
(m
g d
l–1
 
X 
m
in
)
(104)
Ad-MOCK + vehicle
Ad-MOCK + MK2206
Ad-CRY1 + MK2206
Ad-MOCK + vehicle
Ad-MOCK + MK2206
Ad-CRY1 + MK2206
PTT
###
## ##
##
*
**
280
240
200
160
120
80
40
0 30 60 90
Time (min)
Bl
oo
d 
gl
uc
os
e 
(m
g d
l–1
)
a b
c d
e f
g h i
Figure 5 | Long-term insulin treatment stimulates CRY1 expression and inhibits hepatic gluconeogenesis. (a,b) Mouse primary hepatocytes were
treated with 10 nM insulin for different periods. Protein levels (a) were determined with western blotting. The mRNA levels (b) were analysed by qRT-PCR.
Data are represented as mean ±s.d., N¼ 3 for each group. *Po0.05, ***Po0.001 (Student’s t-test). (c–e) Mouse primary hepatocytes isolated from
CRY1þ /þ and CRY1 / mice were treated with 10 nM insulin for different periods. Protein levels (c) were analysed by western blotting, and relative
mRNA levels (d) were determined by qRT-PCR and normalized to the TBP mRNA level. Data are represented as mean ±s.d., N¼ 3 for each group.
*Po0.05, **Po0.01, ***Po0.001 versus CRY1þ /þ control (Student’s t-test). Relative glucose production (e) was measured using a glucose oxidase
(GO) kit. Data are represented as mean±s.d., N¼ 5 for each group. *Po0.05, **Po0.01, versus CRY1þ /þ control (Student’s t-test). (f) Mouse primary
hepatocytes were infected with Ad-MOCK and Ad-CRY1, and then treated with insulin (10 nM) or insulin (10 nM) and AKTVIII (5 mM) for 12 h.
Protein levels were determined with western blotting. (g–i) C57BL/6 mice were infected with Ad-MOCK or Ad-CRY1 and subjected to the pyruvate
tolerance test (g) with or without the AKT inhibitor MK2206. MK2206 (30mg kg 1) was given by oral gavage 10min before the pyruvate tolerance test.
All mice were fasted at ZT 10 and performed PTT at ZT 3. Results were converted to AUC values (h). After the pyruvate tolerance test, hepatic
protein levels (i) were analysed by western blotting. Data are represented as mean ±s.d., N¼ 5–7 for each group. ##Po0.01, ###Po0.001 versus
Ad-MOCKþvehicle control, *Po0.05, **Po0.01, versus Ad-MOCKþMK2206 control (Student’s t-test). See Supplementary Fig. 13 for original
full immunoblot.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12180 ARTICLE
NATURE COMMUNICATIONS | 7:12180 | DOI: 10.1038/ncomms12180 | www.nature.com/naturecommunications 7
treated cells, implying that CRY1 could downregulate FOXO1
protein independent of FOXO1 phosphorylation (Fig. 5f). To
conﬁrm this observation in vivo, we tested another AKT
inhibitor, MK2206, in mice. As shown in Fig. 5g,h, administration
of MK2206 signiﬁcantly increased blood glucose level on pyruvate
challenge; however, adenoviral CRY1 overexpression in mice
signiﬁcantly attenuated blood glucose level even in the presence
of MK2206. It is noteworthy that the level of FOXO1 protein
was greatly augmented by MK2206, whereas CRY1 elevation
suppressed FOXO1 protein expression in vivo (Fig. 5i). Taken
together, these data clearly indicate that CRY1-dependent
FOXO1 reduction may contribute to the suppression of hepatic
gluconeogenesis independent of AKT activation.
CRY1 stimulates proteasomal degradation of FOXO1. Since
CRY1 overexpression decreased the level of the FOXO1 protein,
but not the FOXO1 mRNA, we investigated whether the down-
regulation of the FOXO1 protein might proceed via proteasomal
degradation. As shown in Fig. 6a, the reduction of the FOXO1
protein by CRY1 overexpression was alleviated by MG132
treatment, indicating that the regulation of FOXO1 protein by
CRY1 may be, at least in part, dependent on proteasomal
degradation. When we tested physical interaction between
FOXO1 and CRY1 proteins, co-immunoprecipitation assays
revealed that CRY1 could associate with FOXO1 protein (Fig. 6b).
Then, we examined whether CRY1 might induce FOXO1
degradation via the ubiquitination-proteasome pathway. As
shown in Fig. 6c, CRY1 overexpression dramatically promoted
FOXO1 poly-ubiquitination, implying that CRY1 could
potentiate FOXO1 degradation, probably, through protein–
protein interactions.
To further explore the subcellular location of FOXO1
degradation induced by CRY1, the levels of the nuclear and
cytosolic FOXO1 protein were investigated. As shown in Fig. 6d,
the nuclear fraction of the FOXO1 protein was decreased by
CRY1 overexpression whereas incubation with MG132 blocked
this decrease. At the same time, the levels of cytosolic FOXO1
were not altered on CRY1 overexpression, irrespective of
the presence of MG132. Consistent with these results, poly-
ubiquitination of the nuclear form of the FOXO1 mutant protein
(nFOXO1-MYC) was greatly augmented by CRY1 (Fig. 6e).
Therefore, it is plausible that the degradation of the FOXO1
protein via poly-ubiquitination is stimulated by CRY1 in the
nucleus.
CRY1 is involved in MDM2-mediated FOXO1 degradation.
Among several ubiquitin E3 ligases of the FOXO1 protein45,46, we
found that the MDM2 ubiquitin E3 ligase appeared to be involved
in the CRY1-mediated FOXO1 degradation. As shown in Fig. 7a,
MDM2 suppression markedly rescued the level of the FOXO1
protein in CRY1-overexpressing cells, implying that MDM2 may
participate in the CRY1-dependent FOXO1 reduction. To study
the role of CRY1 in MDM2-mediated FOXO1 degradation, we
tested whether CRY1 might regulate the subcellular localization
of MDM2. Wild-type CRY1 and cytosolic CRY1 (DNLS-CRY1)
did not change the subcellular location of the nuclear MDM2
(Supplementary Fig. 8). Instead, we revealed that CRY1
potentiates the association between FOXO1 and MDM2 (Fig. 7b).
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In another experiment, we explored whether CRY1 could
modulate MDM2-mediated FOXO1 degradation. As shown in
Fig. 7c,d, CRY1 overexpression promoted MDM2-mediated
poly-ubiquitination of the nuclear form of FOXO1 protein
(Fig. 7c), whereas CRY1 suppression attenuated FOXO1 poly-
ubiquitination by MDM2 (Fig. 7d). These data indicate that
CRY1 would participate in MDM2-induced FOXO1 degradation
and repress FOXO1-mediated hepatic glucose production.
CRY1 mitigates hyperglycaemia in diabetic mouse models.
Streptozotocin (STZ)-treated insulin-deﬁcient mice elevated
blood glucose as well as gluconeogenic programs including
FOXO1 protein levels, accompanied with increased expression of
PEPCK and G6Pase genes (Fig. 8a–c). Since the SREBP1c-CRY1
axis was upregulated by insulin (Figs 1c,2e), we overexpressed
CRY1 in the liver of STZ-treated insulin-deﬁcient mice. As shown
in Fig. 8d, CRY1 overexpression diminished blood glucose levels
in STZ-treated mice. In addition, CRY1 reduced not only the
expression of PEPCK and G6Pase genes but also the level
of FOXO1 protein (Fig. 8e,f). These data suggest that CRY1
would be one of important factors to suppress hepatic glucose
production on insulin.
Intriguingly, in the liver of obese animals such as db/db and
diet-induced obesity mice, SREBP1c level is elevated while hepatic
gluconeogenesis is not repressed47–50. To explore which
process(es) might be dysregulated in the regulation of hepatic
gluconeogenesis, we have examined several mRNA and protein
levels for SREBP1c-CRY1 axis and gluconeogenic genes in
diabetic animals. Similar to previous reports47–50, the mRNA
levels of SREBP1c and gluconeogenic genes were elevated in db/db
mice (Fig. 8g). However, hepatic CRY1 protein was substantially
decreased and the level of MDM2 protein was not signiﬁcantly
changed in db/db mice (Fig. 8h). Similarly, diet-induced
obesity mice exhibited elevated expression of SREBP1c and
gluconeogenic genes whereas CRY1 was not activated
(Supplementary Fig. 9A,B). To test the idea that dysregulated
CRY1 protein might mediate hyperglycaemia with enhanced
FOXO1 protein in diabetic animals, CRY1 was adenovirally
overexpressed in the liver of db/db mice. As shown in Fig. 8i, the
levels of pyruvate-induced blood glucose were decreased in
CRY1-overexpressing db/db mice. Moreover, the levels of feeding
blood glucose were diminished by CRY1 overexpression (Fig. 8j).
In addition, ectopic CRY1 expression reduced the levels of
FOXO1 protein as well as gluconeogenic gene expression in db/db
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ZT 3 after 1 week later. Blood glucose levels (a) were measured in ad libitum at ZT 3. After all of the mice were sacriﬁced at ZT 3, hepatic protein levels
(b) were analysed by western blotting. The mRNA levels (c) were determined by qRT-PCR analyses and normalized to the TBP mRNA level. Data represent
mean ±s.d., N¼ 3 for each group. *Po0.05, **Po0.01, ***Po0.001 (Student’s t-test). (d–f) STZ-injected mice were infected with adenovirus encoding
MOCK or CRY1 (adenoviral dose of 2 109 viral particles per mouse). The blood glucose levels (d) were measured in ad libitum at ZT 3. After all of the
mice were sacriﬁced at ZT 3, the mRNA levels (e) were determined by qRT-PCR analyses and normalized to the TBP mRNA level. Hepatic protein levels
(f) were analysed by western blotting. Data represent mean±s.d., N¼4 for each group. *Po0.05, **Po0.01 (Student’s t-test). (g,h) Ten-week-old male
db/þ and db/db mice were sacriﬁced in ad libitum at ZT 3. The relative mRNA levels of various hepatic genes (g) were determined by qRT-PCR analyses
and normalized to the TBP mRNA level. Data represent mean±s.d., N¼4 for each group. *Po0.05 (Student’s t-test). Protein levels (h) were determined
with western blotting. (i–l) Ten-week-old male db/dbmice were infected through the tail vein with adenovirus encoding MOCK or CRY1 (adenoviral dose of
2 1010 viral particles per mouse) and subjected to the pyruvate tolerance test (i). All mice were fasted at ZT 10 and performed PTTat ZT 3. Results were
converted to AUC. The blood glucose levels (j) were measured in ad libitum at ZT 3. After all of the mice were sacriﬁced at ZT 3, hepatic protein levels
(k) were analysed by western blotting. The mRNA levels (l) were determined by qRT-PCR analyses and normalized to the TBP mRNA level. Data represent
mean ±s.d., N¼ 5 for each group. *Po0.05, **Po0.01, ***Po0.001 (Student’s t-test). See Supplementary Fig. 13 for original full immunoblot.
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mice (Fig. 8k,l). These results indicate that CRY1 could
ameliorate hyperglycaemia by repressing the level of FOXO1
protein in db/db mice.
Discussion
As a major anabolic hormone, insulin stimulates lipogenesis and
represses gluconeogenesis in the liver. Following insulin exposure,
lipogenesis is upregulated by SREBP1c, and the expression
of SREBP1c target genes such as FASN, SCD and ELOVL6
is induced20,51,52. In contrast, insulin blocks hepatic
gluconeogenesis through AKT-mediated phosphorylation of
FOXO1 and PGC1a53,54, both are major regulators of
gluconeogenic genes including PEPCK and G6Pase. Here we
propose that the SREBP1c-CRY1 signalling pathway plays an
important role to inhibit hepatic gluconeogenesis under anabolic
state. Our data from hepatic gluconeogenic gene expression,
in vitro glucose output assays, time kinetics of insulin signalling
cascades, and pyruvate tolerance test, which reﬂects both hepatic
glucose output and peripheral glucose disposal, have consistently
suggested the idea that maintenance of SREBP1c-induced
CRY1 is crucial to prevent unnecessary hepatic gluconeogenesis
during insulin action. In this regard, it has been reported that
single-nucleotide polymorphisms of SREBP1c and CRY1 genes
are associated with hyperglycaemia in human55,56.
Similar to previous reports47,48,50, the expression of SREBP1c
and gluconeogenic genes was increased in the liver of diabetic
db/db mice (Fig. 8g,h). Unexpectedly, the level of hepatic CRY1
protein was downregulated in db/db mice. Moreover, in the liver
of db/db mice, diurnal expression of CRY1 protein level was
overall reduced whereas FOXO1 protein levels were elevated
compared to db/þ mice (Supplementary Fig. 10A,B). In this
work, we have demonstrated that ectopic overexpression of CRY1
in db/db mice alleviated hepatic gluconeogenesis by reducing
FOXO1 protein (Fig. 8i–l). Also, we have shown that hepatic
CRY1 could attenuate the level of blood glucose by decreasing
FOXO1 protein, independent of AKT activity (Fig. 5f–i).
Although it remains to be elucidated how elevated SREBP1c
fails to increase CRY1 in the liver of db/db mice, it is very likely
that increased FOXO1 protein results from reduced hepatic CRY1
protein in db/db mice.
It has been reported that CRY1 seems to suppress hepatic
glucose production by interfering with glucocorticoid receptor
signalling and the glucagon signalling pathway33–35. CRY1
interacts with glucocorticoid receptor34 and the a-subunit of
the glucagon receptor33, which are involved in the regulation of
gluconeogenesis. Nonetheless, speciﬁc roles of CRY1 during the
nutrient-rich state after exposure to insulin have not been clearly
elucidated. To test whether CRY1 might repress gluconeogenesis
by inhibiting glucagon signalling and/or glucocorticoid receptor-
dependent pathway, CRY1-overexpressing primary hepatocytes
were treated with forskolin, db-cAMP or dexamethasone to
mimic the conditions for glucagon or glucocorticoid stimulation.
In primary hepatocytes, CRY1 partially repressed gluconeogenic
gene expression in the presence of forskolin, db-cAMP or
dexamethasone (Supplementary Fig. 11A–C), implying that in
addition to the glucagon and glucocorticoid signalling pathways,
there may be another signalling cascade regulated by CRY1,
which could suppress hepatic glucose production. Thus, CRY1
appears to be involved in multiple regulatory pathways
that control hepatic gluconeogenesis in response to various
hormones.
Activation of FOXO1-mediated gluconeogenesis is inhibited by
insulin. AKT, a key downstream molecule of the insulin-activated
signalling, phosphorylates FOXO1, which then is translocated
from the nucleus to the cytoplasm through its association
with the 14-3-3 protein57. In primary hepatocytes, FOXO1
phosphorylation was rapidly increased by insulin. However,
hepatic gluconeogenic programing is persistently and efﬁciently
suppressed regardless of the decreased FOXO1 phosphorylation
at the late stage of insulin action. Intriguingly, hepatic CRY1
expression was enhanced at relatively late periods of insulin
action (Fig. 5a). Furthermore, in primary hepatocytes, a long-
term insulin treatment downregulated FOXO1 expression, while
CRY1 deﬁciency rescued FOXO1 protein levels as well as
gluconeogenic gene expression (Fig. 5c,d). It is of interest to
note that CRY1-overexpressing mice showed a decrease of blood
glucose level as well as of FOXO1 protein when AKT activity was
pharmacologically repressed with AKT inhibitor MK2206
(Fig. 5g–i). Collectively, our in vitro and in vivo data suggest
that the CRY1-dependent FOXO1 degradation would be one of
the crucial mechanisms in attenuating hepatic gluconeogenesis
for the long-term insulin action. Therefore, these observations
prompted us to propose that the AKT-mediated FOXO1
phosphorylation provides an acute response during early insulin
response, whereas SREBP1c-mediated CRY1 regulation would be
a more durable process leading to the repression of futile hepatic
gluconeogenesis throughout the anabolic state (Fig. 9).
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Figure 9 | SREBP1c-CRY1 axis suppresses hepatic gluconeogenesis by promoting FOXO1 degradation. For long-term insulin action, SREBP1c-CRY1 axis
suppresses hepatic gluconeogenesis through nuclear FOXO1 degradation. During anabolic state, increased CRY1 accelerates MDM2-mediated FOXO1
degradation and thereby insulin sustainably represses hepatic glucose production.
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As one of the key players for circadian rhythmic modulation,
CRY1 expression is affected by various transcription factors and
epigenetic regulation. Although our in vivo and in vitro data
suggested that CRY1 expression was promoted by insulin and
SREBP1c, CRY1 mRNA expression was not elevated by refeeding
at ZT 10, which is the trough point of CRY1 oscillation
(Supplementary Fig. 2B). These data propose that increased
SREBP1c might not be sufﬁcient to activate CRY1 at ZT 10.
Conversely, the levels of CRY1 mRNA and proteins were robustly
increased by refeeding at ZT 22, which is the peak point
of its oscillation, implying that SREBP1c would augment
CRY1 expression, probably, accompanied with other circadian
regulatory factors. Nonetheless, it remains to be elucidated
whether CRY1 as well as other circadian clock genes may
contribute to modulate hepatic gluconeogenesis at ZT 22.
On the other hand, we asked the question whether SREBP1c
deﬁciency would change hepatic circadian clock gene oscillation.
As shown in Supplementary Fig. 12, hepatic circadian clock gene
oscillations were not signiﬁcantly different in SREBP1cþ /þ and
SREBP1c / mice. Of course, we cannot exclude the possibility
that SREBP1c-induced CRY1 might contribute to minor roles for
hepatic circadian oscillation in SREBP1c / mice because it has
been reported that CRY1 / mice exhibit fewer changes in
circadian oscillations, compared with CRY1 /CRY2 /
double-mutant mice58. Furthermore, it is also possible that
remaining SREBP1a and/or SREBP2 activity in SREBP1c /
mice might maintain intact circadian clock gene oscillations and
this homoeostatic regulation needs to be addressed in future
studies21,59. Nonetheless, hepatic CRY1 gene expression is clearly
upregulated by feeding/insulin-mediated SREBP1c.
Consistent with previous reports31, hepatic CRY1 was increased
at night time (ZT 12–24) when feeding behaviour dominantly
occurs in nocturnal animals (Supplementary Fig. 10A). Although
SREBP1c / mice did not show any signiﬁcant difference of
circadian clock oscillation (Supplementary Fig. 12), SREBP1c
expression was also increased at night time (ZT 12–24;
Supplementary Fig. 10). Unlike the expression proﬁles of
SREBP1c and CRY1, the level of FOXO1 protein appeared to be
reduced at night time, implying that circadian oscillations of
SREBP1c and CRY1 may contribute to repress diurnal glucose
production by the regulation of FOXO1.
As SREBP1c could simultaneously regulate both gluconeo-
genesis and lipogenesis, it is plausible to speculate that hepatic
SREBP1c would effectively coordinate the anabolic pathways by
upregulating fatty acid metabolism and downregulating glucose
metabolism on insulin signalling with different target genes. Our
study is the ﬁrst report to reveal the role of SREBP1c in CRY1
activation, which would be crucial in the regulation of hepatic
glucose metabolism in the anabolic state. On the basis of the
circadian oscillatory gene expression proﬁle in SREBP1c /
mice, it appears that SREBP1c does not actively govern the
hepatic circadian clock. Rather, increased expression of hepatic
CRY1 during the postprandial state is primarily regulated, in a
clock-gated manner, by insulin-activated SREBP1c, which
eventually leads to the suppression of glucose production via
FOXO1 degradation (Fig. 9). Although the roles of hepatic CRY1
in energy metabolism need to be investigated further, our
data provide an important clue to understand the molecular
mechanisms that link hepatic SREBP1c and glucose homoeostasis
in physiological and pathological conditions.
Methods
Animals. C57BL/6 male mice were purchased from SAMTACO (Seoul, South
Korea) and housed in colony cages. db/þ and db/db male mice were obtained
from Central Lab (Seoul, Korea). SREBP1c / mice were generously provided
from Dr J. Horton at the University of Texas Southwestern Medical Center and
bred in isolated cages. All animals were maintained under 12 h light/12 h dark cycle
in a pathogen-free animal facility. Following dissection, mouse tissue specimens
were immediately stored at  80 C until further analysis. All experiments with
mice were approved by the Seoul National University Institutional Animal Care
and Use Committee (SNUIACUC) and the Institutional Animal Care and Use
Committee at the University of North Carolina.
In vivo imaging system. Ten-week-old C57BL/6 male mice were injected with
adenoviruses encoding green ﬂuorescent protein (GFP) (Ad-MOCK), SREBP1c
(Ad-SREBP1c) and G6Pase luciferase (Ad-G6Pase-luc) through the tail vein. After
5 days, adenovirus-infected mice were injected intraperitoneally with 100mg kg 1
sterile ﬁreﬂy D-luciferin. After 5min, mice were anaesthetised and imaged using an
IVIS 100 imaging system (Xenogen, Alameda, CA, USA) as described60.
Pyruvate tolerance tests. For the pyruvate tolerance test, mice were fasted for
16 h and then injected intraperitoneally with pyruvate (2 g kg 1 body weight
for mice). Blood glucose levels were measured in tail vein blood samples at the
indicated time points by using a Free-Style blood glucose metre (TheraSense,
Sweden).
Materials and plasmids. MG132 was purchased from Calbiochem (San Diego,
CA, USA). MK2206 was purchased from Selleckchem (S1078). AKTVIII was
purchased from Santa Cruz Biotechnology (sc-202048). Antibodies against MYC
(Cell Signalling, 2276, 1:1,000 dilution), HA (Cell Signalling, 3724, 1:1,000
dilution), FOXO1 (Cell Signalling, 2880, 1:1,000 dilution), phosphor-FOXO1-
Ser256 (Cell Signalling, 9461, 1:1,000 dilution), AKT (Cell Signalling, 9272, 1:1,000
dilution), and phosphor-AKT-Ser473 (Cell Signalling, 9271, 1:1,000 dilution),
FLAG (Sigma-Aldrich, F3165, 1:1,000 dilution), ACTIN (Sigma-Aldrich, A5316,
1:2,000 dilution), G6Pase (Santa Cruz Biotechnology, sc-33839, 1:500 dilution),
POLII (Santa Cruz Biotechnology, sc-899, 1:1,000 dilution), GFP (Santa Cruz
Biotechnology, sc-9996, 1:1,000 dilution), GAPDH (LabFrontier, Co., LF-PA0018,
1:1,000 dilution), SREBP1 (BD Bioscience, 557036, 1:1,000 dilution), MDM2
(Abcam, ab16895, 1:1,000 dilution) and CRY1 (lab made antibody from
Dr Aziz Sancar31, 1:200 dilution) were used. GFP-CRY1 was cloned into the
pEGFP-N1 vector and FLAG-MDM2 was cloned into pCMV-3 FLAG. Mouse
CRY1 promoter was cloned into the pGL3-basic vector.
Cell-based ubiquitination assays. COS-1 cells (ATCC, CRL1650) were
transfected with plasmids encoding FOXO1 WT-MYC, nFOXO1 (ADA)-MYC,
GFP-CRY1 (or FLAG-CRY1), FLAG-MDM2 and Ubiquitin-HA in the presence of
20 mM MG132 for 4 h. Total cell lysates were prepared using the TGN buffer.
FOXO1 WT-MYC and nFOXO1 (ADA)-MYC were immunoprecipitated with an
anti-MYC antibody, and after washing in the TGN buffer, proteins were separated
by SDS–PAGE followed by western blotting analyses with an anti-HA antibody.
ChIP assays. Cross-linking and chromatin immunoprecipitation assays with
H4IIE cells (ATCC, CRL1548) were performed as described previously61. Extracted
proteins from total cell lysates were immunoprecipitated with anti-SREBP1 (BD
Bioscience) or IgG (Santa Cruz) for 2 h. Precipitated DNA fragments were analysed
by qRT-PCR using primer sets that encompassed the proximal ( 100 to þ 100
base pairs) region of the rat CRY1 promoter and negative control (þ 9670 to
þ 9890 base pairs) region. The sequences of ChIP assay primers were as follows:
sense, 50-GTCCGAGCCAGCGTAGTAAA-30 , antisense, 50-GGATAGCGCGGG
CTAGAG-30 ; negative control primer sense, 50-CCAGCCACTTTGCTGAAGTT-30
and antisense, 50-CTAGACAAGGCTGCCCACTC-30 .
Preparation of recombinant adenovirus. The adenovirus plasmid was
constructed as previously described62. Rat SREBP1c and mouse CRY1 cDNAs
were incorporated into the AdTrack-CMV shuttle vector and a recombinant
vector was generated using the Ad-Easy adenoviral vector system. Adenoviruses
were ampliﬁed in HEK293A cells and isolated by caesium chloride density
centrifugation. The GFP was co-expressed from an independent promoter with
inserted cDNA. For in vivo experiments, mice were injected with 5 109 p.f.u. of
adenovirus (db/db mice, 2 1010 p.f.u.) in 200 ml PBS through the tail vein. Empty
virus expressing only the gene for GFP served as the control (MOCK).
Mouse primary hepatocytes cultures. Mouse primary hepatocytes were isolated
from 10-week-old male mice using collagenase perfusion method63 and plated with
medium 199 (Invitrogen, Carlsbad, CA, USA). After 6 h of attachment, cells were
infected with adenovirus or transfected with siRNA. For adenoviral infection,
isolated hepatocytes were incubated for 4 h with adenovirus at 10 PFU per cell
with the serum-free medium, which was subsequently replaced by the 10%
FBS-containing M199 medium.
Cell lysis and immunoprecipitation. After washing in cold PBS, cells were treated
either with the TGN buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl, 1% Tween-20
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and 0.3% NP-40) or the SDS lysis buffer (200mM Tris-HCl, pH 6.8, 10% glycerol
and 4% SDS) supplemented with 0.1% protease inhibitor cocktail (Roche, Basel,
Switzerland). Total cell lysates were obtained by centrifugation at 12,000 r.p.m. for
15min at 4 C, and 1–1.5mg of lysates was used for immunoprecipitation. The
lysates were incubated with primary antibodies for 2 h at 4 C, followed by 1 h of
further incubation with 50% slurry of protein A sepharose presaturated with the
lysis buffer. After washing three times with the lysis buffer, the immunoprecipitated
proteins were recovered from the beads by boiling for 10min in the sample buffer
and analysed by SDS–PAGE and immunoblotting.
Transient transfection and luciferase assays. HEK293T cells (ATCC, CRL3216)
were transiently transfected with various DNA plasmids using the calcium-
phosphate method described previously64. After incubation for 36 h, transfected
cells were collected with the lysis buffer (25mM Tris-phosphate pH 7.8, 10%
glycerol, 2mM EDTA, 2mM DTT and 1% Triton X-100) and the activities of
luciferase and b-galactosidase were measured according to the manufacturer’s
protocol (Promega, Madison, WI, USA). The relative luciferase activity was
normalized to b-galactosidase activity in each sample.
RNA preparation and quantitative reverse transcriptase–PCR analyses. RNA
was prepared as previously described65. Brieﬂy, total RNA was isolated using the
TRIzol reagent (Invitrogen). Subsequently, equal amounts of RNA were subjected
to cDNA synthesis using the RevertAid M-MuLV reverse transcriptase (Fermentas,
Canada). The relative amount of mRNA was evaluated by using a CFX real-time
quantitative PCR detection system (Bio-Rad Laboratories, Hercules, CA, USA) and
calculated following normalization to the level of TBP or cyclophilin mRNA. The
primer sequences used for the real-time quantitative PCR analyses are described in
the Supplementary Table 1.
siRNA transfection. siRNA duplexes for CRY1, MDM2, and FOXO1 were
purchased from the Bioneer, Inc. (Daejeon, South Korea). Primary hepatocytes
were transiently transfected with the Lipofectamine RNAi MAX reagent
(Invitrogen) according to the manufacturer’s protocol. The sequence information
for siRNA is described in the Supplementary Table 2.
Glucose production assays. Glucose production by mouse primary hepatocytes
was measured according to the manufacturer’s protocol using a glucose oxidase
assay (Sigma-Aldrich, St Louis, MO, USA). Brieﬂy, the cells were incubated for 6 h
at 37 C and 5% CO2 in the Krebs-Ringer buffer (115mM NaCl, 5.9mM KCl,
1.2mM MgCl2, 1.2mM NaH2PO4, 2.5mM CaCl2, 25mM NaHCO3, 10mM lactate
and 2mM pyruvate, pH 7.4). The glucose production assays were performed in
triplicate.
Statistical analysis. Sample sizes were chosen based on pilot experiments that
ensured adequate statistical power with similar variances. Statistical signiﬁcance
was assessed by the Student’s t-test and are presented as the mean±s.d.
determined from at least three independent experiments. Values of Po0.05 were
considered to indicate statistically signiﬁcant differences. All n values deﬁned in the
legends refer to biological replicates unless otherwise indicated. If technical failures
such as failure of intraperitoneal injection occurred, those samples were excluded
from the ﬁnal analysis. The experiments were not randomized. The investigators
were not blinded to allocation during experiments and outcome assessment.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author on reasonable request.
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